Neurizon Therapeutics Limited · ASX:NUZ
Neurizon Therapeutics — Investor Presentation (June 2020)
17 slides from Neurizon Therapeutics's investor presentation, Jun 10, 2020
Slide 1: Virtual Investor Briefing Presentation
VIRTUAL INVESTOR BRIEFING PRESENTATION 10 June 2020 – Perth, Australia: PharmAust Limited (ASX:PAA), a clinical-stage oncology company, is pleased to provide the investor presentation to be delivered during today’s Virtual Investor Briefing to be held at 12.00 pm AWST / 2:00 pm AEST. Executive Chair
Slide 2: Pitney Pharmaceuticals and Epichem subsidiaries
100% 100% Pitney Pharmaceuticals Pty Ltd: Epichem Pty Ltd: “repurposing” Monepantel in Medicinal & Synthetic Chemistry oncology and in mTOR Disease Expected 2019-2020 sales A$ 3.46m+ Shareholder Update Presentation June 2020 1
Slide 3: About PharmAust Limited (ASX:PAA)
About PharmAust Limited (ASX:PAA) • PharmAust is an Australian clinical stage oncology company repurposing the drug Monepantel (MPL) for targeted cancer therapeutics in humans & animals • Successful canine phase II clinical trials recently completed & results to be presented to the MPL compound owne
Slide 4: PharmAust Strategy
PharmAust Strategy Human Phase IIa MPL IN targeted in 2021 HUMAN CANCER Contract business & MPL program Phase I/Phase II complete support MPL IN Phase II/III registration EPICHEM CANINE study to begin 2020 CANCER PHARMAUST mTOR Interest in MPL SARS- DISEASES for mTOR diseases CoV-2 Shareholder Updat
Slide 5: mTOR – What Does It Do
mTOR – What Does it Do GROWTH AMINO OXYGEN FACTORS ACIDS GROWTH FACTORS mTORC1 mTOR mTORC2 LIPID AND NUCLEOTIDE SYNTHESIS PROTEIN SYNTHESIS AND SURVIVAL AND AUTOPHAGY PROLIFERATION CELL GROWTH https://www.abc.net.au/radionational/programs/healthreport/battling-mutating-cancer-cells/12326932 Sharehol
Slide 6: PharmAust – Current Status
PharmAust – Current Status • Outcome of Phase II B Cell lymphoma veterinary clinical trial PHASE II • 100% Survival during the trial (Typically 50% of untreated dogs CANINE TRIAL would not survive for 28 days) • 1 canine showed highly significant 60% regression of all of its tumours with one tumour
Slide 7: Monepantel (MPL) In Oncology
Monepantel (MPL) In Oncology A UNIQUE ANTI-CANCER PARADIGM • Availability of GMP • Very low toxicity Manufacture Allows quality drug on normal cells in place high dose through • mTOR REGULATOR therapy partner Access to Validation • Already registered registration • Mice, canines & man: as a veterina
Slide 8: PharmAust Commercial Catalysts
PharmAust Commercial Catalysts MPL Repurposing drug approved for veterinary use PATENTS PharmAust has granted patents for the use MPL in cancer & other diseases MPL ready for dose optimisation & evaluation CLINICAL for use in standard of care in vet (Phase III) STRATEGY & Phase IIa in man COVID-19 N
Slide 9: Intellectual Property
INTELLECTUAL PROPERTY Numerous Cancers included in Patents for MPL mTOR Pathway for Aminoacetonitriles Synergy & Benefit of Combinations with other Cancer Treatments Cover for numerous analogues of MPL Use of MPL and aminoacetonitrile in COVID-19 Shareholder update presentation June 2020 8
Slide 10: Vet Major Animal Health – Option Agreement
Vet Major Animal Health – Option Agreement • Monepantel compound is owned by Vet Major, approved for treatment of parasitic infections in sheep (patent protection to 2024) • Option agreement with Vet Major to exclusive, worldwide royalty bearing license to commercialise MPL for treatment of cancer i
Slide 11: SARS-CoV-2 – COVID-19
SARS-CoV-2 – COVID-19 • Vaccines will take time to test & introduce • Changes in the viral structure may require changes to the vaccine • Other than remdesivir little available to treat pre or • Reduced virus post intensive care stage RNA • Reduced infectivity Illustrations, created at the Centers f
Slide 12: >$2 Billion market for approved mTOR Drugs
>$2 Billion market for approved mTOR Drugs THE MORE IMPORTANT LIMITATIONS OF mTOR DRUGS ARE SIDE EFFECTS AND RESISTANCE 2013 – 2019 Approved Compound Company Annual Sales Cancer Side effects Indications (USD million) Transplantation infections Sirolimus Transplantation Sirolimus nausea (rapamycin) P
Slide 13: Initial Market - Pets & Cancer
Initial Market - Pets & Cancer • 6 million dogs diagnosed with cancer annually in the US • Significant unmet need for new oncology drugs (Estimated unpublished reports of US$500m-US$1b market, representing 25% of total available market. 1US market alone = ~USD 100 million) • Side effects associated
Slide 14: PharmAust – Next Steps
PharmAust – Next Steps • Canine trial – Present to Vet Major as per Option Agreement • Re-Open human use programme - >USD52b market • Progression of the human trial including further development of formulation & manufacture of additional tablets • COVID-19 discussions with Walter and Eliza Hall Inst
Slide 15: Epichem Pty Ltd: Medicinal & Synthetic Chemistry Expertise
EPICHEM PTY LTD: Medicinal & Synthetic Chemistry Expertise Worldwide customer base in pharmaceutical, mining, agriculture and animal health sectors State of the art facilities Medicinal Chemistry & Drug Discovery Proven Track Record of Success • Hit-to-Lead projects • SFC chromatography, computation
Slide 16: Experienced Board & Management Team
Experienced Board & Management Team Dr Roger Aston, Executive Chairman & CEO Neville Bassett, Non-Executive Director • > 30 years experience in the pharmaceutical & healthcare • Member of the Order of Australia (AM) industries • > 35 years working in accounting, finance & stockbroking • Director or
Slide 17: Disclaimer
Disclaimer This presentation has been prepared by PharmAust Limited (ASX: PAA) (ACN: 094 006 023) (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents
Neurizon Therapeutics — Investor Presentation (June 2020) on 6ix